Monopar Therapeutics Inc. (MNPR) Stock Forecast
MNPR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 12 analysts
- Price target
- $129.92 average of analyst targets
- Upside to target
- +87.6% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.86
- 52-week range
- $50.12 – $123.84
MNPR analyst ratings
12 analystsNumber of analysts at each rating.
MNPR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MNPR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.85 | −$1.37 | −$0.37 | −$0.48 | −77.8% | 10 |
| Current fiscal year (2026) | −$3.04 | −$5.25 | −$1.88 | −$1.85 | −64.3% | 10 |
| Next fiscal year (2027) | −$1.92 | −$5.30 | $7.11 | −$3.04 | +37.0% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MNPR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 10 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 10 |
| Next fiscal year (2027) | $28.3M | $0 | $132.8M | 0.0% | 9 |
MNPR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MNPR revenue: reported and forecast
MNPR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.77 | −$0.77 | −$0.84 | −$0.84 | −$0.85 | +11.4% | 1 up · 5 down |
| Current fiscal year (2026) | −$2.90 | −$2.90 | −$3.01 | −$3.01 | −$3.04 | +4.7% | 4 up · 4 down |
| Next fiscal year (2027) | −$3.14 | −$3.13 | −$1.98 | −$1.92 | −$1.92 | −38.9% | 3 up · 4 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MNPR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MNPR beat in 7 of 12.
What analysts expect from MNPR
12 analysts cover Monopar Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $129.92, 87.6% above the latest close of $69.27. Analysts expect earnings of −$3.04 per share for 2026, −64.3% from a year earlier. For 2027 the average estimate is −$1.92 per share on revenue of $28.3 million. Monopar Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: MNPR income statement, MNPR key metrics, MNPR chart. See the MNPR stock overview for the latest quote and news.
MNPR forecast FAQ
What is Monopar Therapeutics's price target?
The average analyst price target for Monopar Therapeutics is $129.92, 87.6% above the latest close of $69.27.
Is Monopar Therapeutics a buy, hold or sell?
Of 12 analysts covering Monopar Therapeutics, 7 rate it a strong buy, 4 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Monopar Therapeutics's EPS forecast?
Analysts forecast −$3.04 per share for 2026 (range −$5.25 to −$1.88); for 2027 the estimate is −$1.92.
When does Monopar Therapeutics report earnings?
Monopar Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.86.
Does Monopar Therapeutics usually beat earnings estimates?
Monopar Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.